SCHEMBL3177779

SCHEMBL3177779

Cc1cnccc1C(=O)N(Cc1ccccc1)c1ccccc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.62
KMT2A Q03164 2/20 0.50
TSHR P16473 3/20 0.48
GAA P10253 2/20 0.48
MAPK1 P28482 1/20 0.48
PDK1 Q15118 4/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43
KDM4E B2RXH2 3/20 0.42
TACR1 P25103 1/20 0.42
MEN1 O00255 1/20 0.41
NOTUM Q6P988 1/20 0.41
ALDH1A1 P00352 2/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
KDM6B O15054 1/20 0.41
KDM4A O75164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3057326 0.91 TRPM8 (0.51) TRPM8KMT2ATSHRGAAMAPK1
SCHEMBL3054114 0.90 TRPM8 (0.49) TRPM8KMT2ATSHRGAAMAPK1
SCHEMBL3064381 0.88 RAB9A (0.49) TRPM8KMT2ATSHRGAAMAPK1
SCHEMBL3052135 0.88 TRPM8 (0.48) TRPM8KMT2ATSHRGAAMAPK1
SCHEMBL3062067 0.88 TRPM8 (0.50) TRPM8KMT2ATSHRGAAMAPK1
SCHEMBL3065409 0.88 GAA (0.63) TRPM8KMT2ATSHRGAAPDK1
SCHEMBL3066044 0.87 TRPM8 (0.47) TRPM8KMT2ATSHRGAAPDK1
SCHEMBL3043454 0.86 ALDH1A1 (0.47) TRPM8KMT2ATSHRGAAMAPK1
SCHEMBL3062071 0.86 TRPM8 (0.46) TRPM8KMT2ATSHRGAAMAPK1
SCHEMBL3057428 0.85 TRPM8 (0.45) TRPM8KMT2ATSHRGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS NOVARTIS AG (CH) 2010-10-14 US disclosed
CN-101405268-A Amide derivatives and their use for the treatment of protein-related diseases NOVARTIS AG (CH) 2009-04-08 CN disclosed
EP-2001851-A2 AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES Novartis AG (CH) 2008-12-17 EP disclosed
WO-2007110237-A2 AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES NOVARTIS AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS HRH4, CNR1, CNR2 TRPM8 1707/4885KMT2A 1989/4885TSHR 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.